Bayer’s remorse

The German pharma group’s stock fell more than $14 billion as it made an approach for U.S. seed maker Monsanto. It’s almost as much as the premium Bayer is offering, and suggests shareholders expect next to no cost savings. The deal looks value destructive, but that seems harsh.